2026

Journal Club by KidNEYCAnCeR April 24, 2026

Featured Journal Club Articles

█ EAU guidelines on renal cell carcinoma: the 2025 update Citation: Bex A, Abu Ghanem Y, Albiges L, et al. Eur Urol. 2025;87(6):683–696. doi:10.1016/j.eururo.2025.02.020. PMID: 40118739. Background: The EAU RCC guideline panel conducts annual structured updates of its evidence-based recommendations for the…

GU26 ASCO by KidNEYCAnCeR April 22, 2026

190Views 0Comments

Seleted Presentations from GU ASCO 2026 in Renal Cancer.

This document presents full abstract summaries for the ten kidney cancer abstracts selected by the Editor-in-Chief as the most clinically significant presentations from GU ASCO 2026. Each entry includes background, methods, key results, safety profile, and editorial perspective. Abstracts are ordered by…

GU26 ASCO by KidNEYCAnCeR April 21, 2026

199Views 0Comments

Meeting Summary – GU26 ASCO

Kidney Cancer: Therapeutic Optimization, Biomarker Development, and Emerging Strategies Nirmish Singla, MD, MSc Brady Urological Institute at Johns Hopkins University Introduction The 2026 ASCO Genitourinary Cancers Symposium (GU26), held February 26–28 in San Francisco, California, convened leading clinicians…

GU26 ASCO by KidNEYCAnCeR April 20, 2026

187Views 0Comments

A Watershed Moment for Kidney Cancer: Key Insights from the 2026 ASCO Genitourinary Cancers Symposium

Thomas E Hutson, DO, PharmD Texas Tech University Health Science Center, School of Medicine Lubbock, Texas 79415 Editor-in-Chief, Kidney Cancer Journal The 2026 ASCO Genitourinary Cancers Symposium, convened February 26–28 in San Francisco under the central theme of "Patient-Centered…

Articles by KidNEYCAnCeR April 20, 2026

234Views 0Comments

Molecular and Genomic Biomarkers in Small Renal Masses: A Narrative Review

This narrative review summarizes the current evidence for molecular and genomic biomarkers in SRM risk stratification and evaluates their potential clinical role.

2020 2021 2022 2023 2024 2025 Articles by KidNEYCAnCeR April 2, 2026

302Views 0Comments

Heading One

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…

Articles by KidNEYCAnCeR April 1, 2026

234Views 0Comments

thank-you

Thank you for subscribing to the Kidney Cancer Journal. You're now part of a community dedicated to advancing research, treatment, and hope. We'll be in touch soon

Articles by KidNEYCAnCeR February 21, 2026

488Views 0Comments

The Future of RCC Treatment

Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…

Articles by KidNEYCAnCeR February 20, 2026

669Views 0Comments

Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…

Articles by KidNEYCAnCeR February 20, 2026

453Views 0Comments

The New Frontier: Advancements in Kidney Cancer Treatment

Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD Dear colleagues, The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…

Yearly Archives: 2026

Featured Journal Club Articles

Seleted Presentations from GU ASCO 2026 in Renal Cancer.

Meeting Summary – GU26 ASCO

A Watershed Moment for Kidney Cancer: Key Insights from the 2026 ASCO Genitourinary Cancers Symposium

Molecular and Genomic Biomarkers in Small Renal Masses: A Narrative Review

Heading One

thank-you

The Future of RCC Treatment

Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond

The New Frontier: Advancements in Kidney Cancer Treatment

About Us

Contents

Follow Us

Guidelines

Patient Resources